WO2007027842A1 - Derives d'anilinopyrazole utilises dans le traitement du diabete - Google Patents

Derives d'anilinopyrazole utilises dans le traitement du diabete Download PDF

Info

Publication number
WO2007027842A1
WO2007027842A1 PCT/US2006/033957 US2006033957W WO2007027842A1 WO 2007027842 A1 WO2007027842 A1 WO 2007027842A1 US 2006033957 W US2006033957 W US 2006033957W WO 2007027842 A1 WO2007027842 A1 WO 2007027842A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
mmol
alkyl
halo
methyl
Prior art date
Application number
PCT/US2006/033957
Other languages
English (en)
Inventor
Derek Lowe
Tatiana Shelekhin
Gan Wang
Xin Ma
Christiana Iwuagwu
Shihong Ying
Steven Magnuson
Joachim Rudolph
Johannes Koebberling
Josef Pernerstorfer
Thomas Mueller
Michael Brands
Dirk Heimbach
Niels Lindner
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Priority to CA002620425A priority Critical patent/CA2620425A1/fr
Priority to EP06802675A priority patent/EP1928455A1/fr
Priority to JP2008529258A priority patent/JP2009506127A/ja
Publication of WO2007027842A1 publication Critical patent/WO2007027842A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to anilinopyrazole compounds, pharmaceutical compositions, and methods for treating diabetes and related disorders.
  • Type 1 diabetes or insulin dependent diabetes mellitus (IDDM) arises when patients lack insulin-producing beta-cells in their pancreatic glands.
  • IDDM insulin dependent diabetes mellitus
  • Type 2 diabetes or non-insulin dependent diabetes mellitus (NIDDM) occurs in patients with impaired beta-cell function and alterations in insulin action.
  • the current treatment for type 1 diabetic patients is injection of insulin, while the majority of type 2 diabetic patients are treated with agents that stimulate beta-cell function or with agents that enhance the tissue sensitivity of the patients towards insulin.
  • the drugs presently used to treat type 2 diabetes include alpha-glucosidase inhibitors, insulin sensitizers, insulin secretagogues, and metformin. Over time, almost one-half of type 2 diabetic subjects lose their response to these agents. Insulin treatment is instituted after diet, exercise, and oral medications have failed to adequately control blood glucose. The drawbacks of insulin treatment are the need for drug injection, the potential for hypoglycemia, and weight gain.
  • new therapies to treat type 2 diabetes are needed.
  • new treatments to retain normal (glucose-dependent) insulin secretion are needed.
  • Such new drugs should have the following characteristics: dependency on glucose for promoting insulin secretion (i.e., compounds that stimulate insulin secretion only in the presence of elevated blood glucose); low primary and secondary failure rates; and preservation of islet cell function.
  • the compounds of this invention are believed to provide such benefits.
  • the invention provides anilinopyrazole derivatives of formula (I)
  • R is H or (Ci-C 2 )alkyl; R 1 is H,
  • (C 3 -C 6 )cycloalkyl optionally substituted with up to two substituents selected from the group consisting of (C 1 -C 3 )alkyl, CF 3 , and halo, (C 1 -C 3 )haloalkyl, or phenyl or pyridyl optionally substituted with up to two substituents selected from the group consisting of halo,
  • (C 1 -C 6 )alkyl optionally substituted with one (Q-GOalkoxy, (C 3 -C 6 )cycloalkyl (Q-C ⁇ alkoxy,
  • R 2 is H, halo, (C r C 6 )alkyl
  • R 3 represents an aromatic 5- or 6-membered heteroaryl ring which is optionally fused to phenyl, said heterocycle or fused heterocycle is optionally substituted with up to three substituents selected from
  • R 4 Is (Q-GOalkyl, (C 3 -C 6 )cycloalkyl,
  • n 0, 1, 2, or 3;
  • X is CO 2 R 8 , CONR 5 R 6 , or SO 2 NHR 7 ;
  • R 5 is H
  • R 6 is H or (Ci-C 6 )alkyl
  • R 7 is H or methyl
  • R 8 is H, or
  • the invention relates to a compound of the above first embodiment having the structure
  • R is H or (C 1 -C 2 ⁇ IkVl; R 1 is H,
  • (C 1 -C 6 )alkyl optionally substituted with one (CrC 4 )alkoxy, (C 3 -C 6 )cycloalkyl optionally substituted with up to two substituents selected from the group consisting of (C 1 -C 3 )OIlCyI, CF 3 , and halo, (CrC 3 )haloalkyl, or phenyl optionally substituted with up to two substituents selected from the group consisting of halo,
  • R 2 is H, halo
  • R 3 represents optionally substituted pyridine, optionally substituted pyridazine, optionally substituted pyrimidine, or optionally substituted pyrazine, wherein said optional substituents on R 3 are selected from the group consisting of (C 1 -C 4 JaIkOXy, (C 3 -C 6 )cycloalkoxy (C 1 -C 3 )haloalkoxy, (d-C 6 )alkyl,
  • R 1 is other than H or methyl
  • R 4 is (Ci-C ⁇ alkyl
  • X is CO 2 R 8 , CONR 5 R 6 , or SO 2 NHR 7 ;
  • R 5 is H
  • R 6 is H or (Ci-Qs)alkyl
  • R 7 is H or methyl
  • R 8 is H, or (Ci-COalkyl, or a pharmaceutically acceptable salt thereof.
  • the invention relates to a compound of the above first embodiment having the structure
  • R is H or (Ci-QOalkyl;
  • R 1 is H, (C 1 -C 6 )alkyl optionally substituted with one (C 1 -C 4 )OIkOXy, (C 3 -C 6 )cycloalkyl optionally substituted with up to two substituents selected from the group consisting of (CrC 3 )alkyl, CF 3 , and halo, or (C 1 -C 3 )haloalkyl,
  • R 2 is H, phenyl, 1,3-benzodioxolane, pyridyl or pyrimidyl optionally substituted with up to two substituents selected from the group consisting of
  • R represents an aromatic 5- or 6-membered heteroaryl ring which is optionally fused to phenyl, said heterocycle or fused heterocycle is optionally substituted with up to three substituents selected from
  • R 4 is (Ci-C ⁇ alkyl, (C 3 -C 6 )cycloalkyl,
  • n 0, 1, 2, or 3;
  • X is CO 2 R 8 .
  • R 8 is H, or
  • the invention relates to a compound of the above first embodiment having the structure
  • R is H or (Ci-C 2 )alkyl;
  • R 1 is phenyl or pyridyl optionally substituted with up to two substituents selected from the group consisting of halo,
  • (Ci-C 6 )alkyl optionally substituted with one (C 1 -C-OaIkOXy, (C 3 -C 6 )cycloalkyl (C 1 -CeOaTkOXy,
  • R 2 is H
  • R 3 represents an aromatic 5- or 6-membered heteroaryl ring which is optionally fused to phenyl, said heterocycle or fused heterocycle is optionally substituted with up to three substituents selected from
  • (Ci-C 6 )alkyl optionally substituted with one (Q-GOalkoxy, (C 3 -C 6 )cycloalkyl, and (Q-C ⁇ haloalkyl, halo, cyano,
  • R 4 is (Q-GOalkyl
  • n 0, 1, 2, or 3;
  • X is CO 2 R 8 .
  • R 8 is H, or (Ci-C ⁇ alkyl, or a pharmaceutically acceptable salt thereof.
  • the invention relates to a compound of the above fourth embodiment having the structure
  • R is H or (C r C 2 )alkyl
  • R 1 is phenyl or pyridyl optionally substituted with up to two substituents selected from the group consisting of halo,
  • (C 1 -C 6 )alkyl optionally substituted with one (C 1 -C ⁇ aIkOXy, (C 3 -C 6 )cycloalkyl (C ! -C 6 )alkoxy, (C 3 -C 6 )cycloalkoxy
  • R 2 is H, or
  • R 3 represents optionally substituted pyridine, optionally substituted pyridazine, optionally substituted pyrimidine, or optionally substituted pyrazine, wherein said optional substituents on R are selected from the group consisting of (Ci-CUJalkoxy, (C 3 -C 6 )cycloalkoxy (Ci-C 3 )haloalkoxy,
  • R 4 is (CrC 4 )alkyl
  • n 0, 1, or 2
  • X is CO 2 R 8 .
  • R 8 is H, or (C r C 4 )alkyl, or a pharmaceutically acceptable salt thereof.
  • the invention relates to a compound of the above fifth embodiment having the structure
  • R is H or (Q-C 2 )alkyl
  • R 1 is phenyl substituted in meta-position with one substituent selected from the group consisting of halo,
  • (CrC 6 )alkyl optionally substituted with one (Q-GOalkoxy, (C 1 -C 6 )alkoxy, and (C 3 ⁇ C 6 )cycloalkoxy
  • R 2 is H
  • R 3 represents optionally substituted pyridine, optionally substituted pyi ⁇ dazine, optionally substituted pyrimidine, or optionally substituted pyrazine, wherein said optional substituents on R 3 are selected from the group consisting of
  • (C 1 -C 6 )alkyl optionally substituted with one (Q-GOalkoxy, (C 3 -C 6 )cycloalkyl, (d-C 3 )haloalkyl, halo, and cyano,
  • R 4 is (Ci-C 4 )alkyl
  • n 0, I, or 2
  • X is CO 2 R 8 .
  • R 8 is H, or
  • the invention relates to a compound of the above first embodiment having the formula (I) wherein R is H;
  • R 1 is methyl, ethyl, tert-butyl or cyclopropyl, or phenyl optionally substituted with one substituent selected from the group consisting of
  • R 2 is H, phenyl, pyridyl or pyrimidyl optionally substituted with up to two substituents selected from the group consisting of
  • R 3 represents pyridine, pyrimidine, or pyrazine, optionally substituted with up to two substituents selected from
  • R 4 is (C 1 -C 4 )alkyl
  • n 0, I, or 2;
  • X is CO 2 R 8 .
  • R 8 is H, or
  • halo means F, Br, Cl, and I.
  • (Ci-C 4 )alkyl means a linear or branched saturated hydrocarbon radical having from 1 to 4 C atoms, 1 to 6 C atoms, 2 to 6 C atoms, respectively. Such groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, and the like.
  • (C 3 -C 6 )alkenyl means a linear or branched unsaturated hydrocarbon radical containing a double bond and from 3 to 6 carbon atoms.
  • the double bond may be between any two available carbon atoms in the chain.
  • groups include, allyl, isopropenyl, 2-butenyl, 2-ethyl-2-butenyl, 1-hexenyl, and the like.
  • (C 3 -C 6 )alkynyl means a linear or branched unsaturated hydrocarbon radical containing a triple bond and from 3 to 6 carbon atoms.
  • the triple bond may be between any two available carbon atoms in the chain.
  • Such groups include, propargyl, 2- butynyl, l-methyl-2-butynyl, 3-hexynyl, and the like.
  • (C 3 -C 6 )cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • (Ci-C 3 )alkoxy means a linear or branched saturated hydrocarbon radical having from 1 to 3 C atoms, 1 to 4 C atoms, or 1 to 6 C atoms, respectively, said radical being attached to an O atom.
  • the O atom is the atom through which the alkoxy substituent is attached to the rest of the molecule.
  • groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, butoxy, pentyloxy, hexyloxy, and the like.
  • (C 3 -C 6 )cycloalkoxy includes cyclopropoxy, cyclobutoxy, cyclopentyloxy, and cyclohexyloxy.
  • (Ci-C 3 )haloalkoxy and “(C 2 -C 3 )haloalkoxy” mean a (Ci-C 3 )alkoxy group or a (C 2 -C 3 )alkoxy group, respectively, substituted on C with at least one halogen atom.
  • Such groups include trifluoromethoxy, difluoromethoxy, 2,2-difluoroethoxy, 2,2,2- trifluoroethoxy, 2-chloroethoxy, 3-chloropropoxy, l-fluoro-2,2,-dichloroethoxy, and the like.
  • (C 1 -C 3 )haloalkyl and "(C 2 -C 3 )haloalkyl” mean a (d-C 3 )alkyl group or (C 2 -C 3 )alkyl group substituted on C with at least one halogen atom.
  • groups include trifluoromethyl, difluoroethyl, l-fluoro-2,2-dichloroethyl, 3-chloropropyl, 4-bromohexyl, and the like.
  • C(O) means a radical in which the C atom bears a doubly bonded oxygen, (an oxo substituent) and in which there remains two additional binding sites, that is, represents a radical of the formula:
  • (C r C 4 )acyl means a (C 1 -C 4 )alkyl radical substituted on the C of a C(O) group.
  • the C of the C(O) is the group is also the atom through which the substituent is attached to the rest of the molecule.
  • Such groups include, but are not limited to, acetyl (CH 3 C(O)-), n-propanoyl (CH 3 CH 2 C(O)-), isobutanoyl ((CH 3 ) 2 CHC(O)-), and the like.
  • the formula "NR 8 R 8 means that each of the two possible R 8 groups attached to the
  • N atom is selected independently from the other so that they may be the same or they may be different.
  • (Q-QOalkylthio) and “(C r C 6 )alkylthio” mean a linear or branched saturated hydrocarbon radical having from 1 to 3 C atoms, or 1 to 6 C atoms, respectively, said radical being attached to an S atom.
  • the S atom is the atom through which the alkylthio substituent is attached to the rest of the molecule.
  • SO 2 (C 1 -C 3 )alkyl means a linear or branched saturated hydrocarbon radical having from 1 to 3 C atoms, said radical being attached to the S atom of the SO 2 group.
  • the S atom of the SO 2 group is the atom through which the SO 2 (Ci-C 3 )alkyl substituent is attached to the rest of the molecule.
  • Such groups include methylsulfonyl, ethylsulfonyl, n-propylsulfonyl and isopropylsulfonyl, and the like.
  • 6-membered carbocyclic ring means a partially unsaturated ring containing C atoms fused to the pyrazole ring to form a tetrahydroindazole ring system.
  • the ring may be optionally substituted with (Ci-C 6 )alkyl groups at any available position, up to a total of about 6 C atoms.
  • 5- or 6-membered heterocycles means a saturated 5- or 6-membered ring containing up to two heteroatoms selected from a group consisting of N, O, and S.
  • Such rings include, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, and the like.
  • 5- or 6-membered heteroaryl ring means a unsaturated 5- or 6-membered aromatic ring containing up to 3 atoms independently selected from a group consisting of N,
  • Such rings include, but not limited to, pyridine, pyrimidine, pyrazine, pyridazine, triazine, pyrrole, pyrazole, imidazole, triazole, thiophene, furane, thiazole, isothiazole, oxazole, isoxazole, thiadiazole, oxadiazole, and the like.
  • tetrahydronaphthyl means bicyclic ring radicals of the formulae ' respectively.
  • the radical is attached to the rest of the molecule at any available carbon of the phenyl ring.
  • the substituent may be attached at any available carbon atom.
  • optionally substituted means that the moiety so modified may have from none to up to at least the highest number of substituents indicated.
  • Each substituent may replace any H atom on the moiety so modified as long as the replacement is chemically possible and chemically stable.
  • each substituent is chosen independently of any other substituent and can, accordingly, be the same or different.
  • Also included in the compounds of the present invention are (a) the stereoisomers thereof, (b) the pharmaceutically-acceptable salts thereof, (c) the tautomers thereof, (d) the protected acids and the conjugate acids thereof, and (e) the prodrugs thereof.
  • stereoisomers of these compounds may include, but are not limited to, enantiomers, diastereomers, racemic mixtures, and combinations thereof. Such stereoisomers may be prepared and separated using conventional techniques, either by reacting enantiomeric starting materials, or by separating isomers of compounds of the present invention. Isomers may include geometric isomers. Examples of geometric isomers include, but are not limited to, cis isomers or trans isomers across a double bond. Other isomers are contemplated among the compounds of the present invention. The isomers may be used either in pure form or in admixture with other isomers of the inhibitors described above.
  • Pharmaceutically-acceptable salts of the compounds of the present invention include salts commonly used to form alkali metal salts or form addition salts of free acids or free bases.
  • the nature of the salt is not critical, provided that it is pharmaceutically-acceptable.
  • Suitable pharmaceutically-acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid.
  • Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, heterocyclic, carboxylic, and sulfonic classes of organic acids.
  • organic and sulfonic classes of organic acids includes, but are not limited to, formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2- hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, algenic, N-hydroxybutyric, salicylic, galactaric, and galacturonic acid, and combinations thereof. Tautomers of the compounds of the invention are encompassed by the present invention. Thus,
  • the protected acids include, but are not limited to, esters, hydroxyamino derivatives, amides and sulfonamides.
  • the present invention includes the prodrugs and salts of the prodrugs. Formation of prodrugs is well known in the art in order to enhance the properties of the parent compound; such properties include solubility, absorption, biostability, and release time ⁇ see, e.g.,
  • Major drug biotransformation reactions include iV-dealkylation, 0-dealkylation, aliphatic hydroxylation, aromatic hydroxylation, N-oxidation, S-oxidation, deamination, hydrolysis reactions, glucuronidation, sulfation, and acetylation (see, e.g., Goodman and Gilman's The
  • the compounds used in this invention may be prepared by standard techniques known in the art, by known processes analogous thereto, and/or by the processes described herein, using starting materials which are either commercially available or producible according to routine, conventional chemical methods. The following preparative methods are presented to aid the reader in the synthesis of the compounds of the present invention.
  • Reaction Scheme A illustrates the general method for the preparation of compounds of Formula (Ia), namely, Formula (I) where R is H.
  • An aminopyrazole of Formula (III) is coupled with either a 2-bromo, 2-iodo, or 2-[(trifluoromethyl)sulfonyl]oxy benzoic acid, benzoic ester, benzoic acid amide, or benzenesulfonamide of Formula (IV), using Ullmann- type conditions (copper (II) acetate in DMF, heated in a sealed tube for 16 h) or a 2- bromobenzoic ester, benzoic acid amide, or benzenesulfonamide of Formula (IV) using Buchwald-type conditions (cesium carbonate, BINAP and Pd 2 (dba) 3 in anhydrous toluene, heated to 110 0 C for 16 h under argon).
  • Reaction Scheme B illustrates a general method for conversion of compounds of Formula (Ib) into other Formula (Ia) compounds having at least one R 4 substituent, by reaction of the halogen-containing (Ib) under Suzuki coupling conditions [e.g., a palladium catalyst such as Pd(dppf)Cl 2 , and a boronic acid (V)].
  • Suzuki coupling conditions e.g., a palladium catalyst such as Pd(dppf)Cl 2 , and a boronic acid (V)].
  • Reaction Scheme C outlines a general method for the preparation of other Formula (Ia) compounds from compounds of Formula (Id), which is Formula (I) where R 2 is bromo or iodo.
  • a bromine or iodine is introduced to the compound of Formula (Ic) (Formula (I) where R 2 is H) and the resulting Formula (Id) compound is allowed to undergo a Suzuki reaction with a boronic acid R 2 B(OH) 2 .
  • Formula (Ia) compounds may be prepared containing a variety of R 2 and R 4 substituents as shown in Reaction Scheme D.
  • Reaction Scheme D For example, coupling a dibromobenzoic acid, dibromobenzoic ester, or dibromobenzenesulfonamide of Formula (IVa) with a pyrazole of Formula (HIa) provides an intermediate of Formula (Ie).
  • Suzuki reaction of (Ie) with a boronic acid derivative gives (If) which can be brominated or iodinated to give (Id).
  • (Id) can be converted to the Formula (Ia) compounds via another Suzuki reaction.
  • the reaction is conducted in the presence of a base such as LiNMe 2 or K 2 CO 3 .
  • JVyV-dibenzylsulfonamide compound of Formula (Ir) is prepared as described in Reaction Scheme A and can be de-benzylated with sulfuric acid to give the compound of Formula (Is).
  • the compounds of Formula (I) where R is (Ci-C 2 )alkyl are prepared by iV-alkylation of the corresponding Formula (Ia) compounds where R is H, using standard conditions such as those shown in Reaction Scheme I.
  • Such conditions include an alkylating agent such as iodomethane, and a base such as sodium hydride, and the reaction is carried out in inert solvent such as DMF.
  • 5-Aminopyrazoles 5-Aminopyrazole starting materials of Formula (III) are either commercially available or can be prepared as shown in Reaction Schemes K, Kl, L, or M.
  • R 20 is H, (C 1 -C 4 ) alkyl ( lllc ) ( llld )
  • Suitable boronic acid esters include R 2 B(OR') 2 where R' is a lower alkyl group, or two R' groups may form a ring
  • Reaction Scheme M illustrates how the aminopyrazole of Formula (Ilia) may be converted to other aminopyrazoles of Formula (III) by bromination and Suzuki or Stille coupling reactions to introduce an R 2 group other than H.
  • the product of the Stille reaction (HIc) can also be reduced, for example by hydrogenation, to give the saturated compound of Formula (Illd).
  • Hydrazine starting materials of Formula (II) are either commercially available or, in the case of heteroaryl hydrazines of Formula (Ha) where R 3 is optionally substituted heteroaryl, can be prepared by routes described in Reaction Scheme Nl and N2. Reaction Scheme Nl
  • a substituted aniline is converted into a diazonium salt intermediate which is subsequently reduced using tin(II)chloride as the reductant.
  • Hvdrazones Hydrazone starting materials of Formula (lib) are either commercially available or, can be prepared as shown in Reaction Scheme O.
  • 2-Bromo, 2-iodo, and/or 2-r(trifluoromethyl)sulfonyl1oxy benzoic acid derivatives The 2-bromo, 2-iodo, and/or 2-[(trifluoromethyl)sulfonyl]oxy benzoic acid derivatives used in the coupling reactions with 5-aminopyrazoles were either commercially available or prepared by straightforward means well known in the art.
  • CDI carbonyl diimidazole Celite ® brand of diatomaceous earth filtering agent registered trademark of
  • DOWEX ® 66 Dowex hydroxide, weakly basic anion, macroporous, 25-50 mesh dppf 1 , 1' -bis(diphenylphosphino)ferrocene
  • Air and moisture sensitive liquids and solutions were transferred via syringe or cannula, and introduced into reaction vessels through rubber septa. Commercial grade reagents and solvents were used without further purification.
  • concentration under reduced pressure refers to use of a Buchi rotary evaporator at approximately 15 mm of Hg. All temperatures are reported uncorrected in degrees Celsius ( 0 C).
  • Thin layer chromatography TLC was performed on EM Science pre-coated glass-backed silica gel 60 A F-254 250 ⁇ m plates. Column chromatography (flash chromatography) was performed on a Biotage system using 32-63 micron, 60 A, silica gel pre-packed cartridges.
  • Electron impact mass spectra were obtained with a Hewlett Packard 5989A mass spectrometer equipped with a Hewlett Packard 5890 Gas Chromatograph with a J & W DB-5 column (0.25 ⁇ M coating; 30 m x 0.25 mm). The ion source was maintained at 250 0 C and spectra were scanned from 50-800 amu at 2 sec per scan.
  • HPLC retention times indicated for the specific examples in this invention are either recorded directly under the above HPLC ES-MS conditions, shown in the subsequent tables as (A) and (B), or recorded under one of the following methods:
  • 3-Hydrazino-4-methylpyridine hydrochloride (628 mg, 3.93 mmol) (step 1) and 3,3- dimethyl-2-oxobutanenitrile (532 mg, 4.25 mmol) were dissolved in ethanol (5 mL) in a sealed tube and heated at ⁇ 80 0 C for 15 h. The flask was then cooled to rt, opened, and the solvent was removed under reduced pressure. The crude residue was treated with water, and basified by slow addition of concentrated aq. NaOH solution (ice bath used since highly exothermic). The product was extracted with DCM (3x), the combined organic layers were dried over Na 2 SO 4 and concentrated to give the product as an oil (758 mg, 77 %).
  • ES-MS m/z 231.2 (MH + ); HPLC RT (min) 1.33 ⁇ method (A) ⁇ .
  • Step 3 Preparation of methyl 2- ⁇ r3-teit-butyl-l-(4-methylpyridin-3-yl)-lH-pyrazol-5- yll amino I -5-methoxybenzoate
  • step 2 3-tert-butyl-l-(4-methylpyridin-3-yl)-lH-pyrazol-5- amine (259 mg, 0.56 mmol) (step 2) and methyl 2-bromo-5-methoxybenzoate (114.8 mg, 0.47 mmol) were combined in an oven-dried pressure tube.
  • BESfAP (93.4 mg, 0.094 mmol), Pd 2 dba 3 (85.8 mg, 0.094 mmol), and powdery cesium carbonate (pre-dried in a high vacuum oven) (458 mg, 1.41 mmol) were added subsequently, followed by toluene (2 mL).
  • the pressure tube was sealed and the reaction mixture heated at 80 0 C for 16 h.
  • Step 4 Preparation of 2- ⁇ r3-tert-butyl-l-(4-methylpyridin-3-yl)-lH-pyrazol-5-yllamino ⁇ -5- methoxybenzoic acid
  • Methyl 2- ⁇ [3-tert-butyl-l-(4-methylpyridin-3-yl)-lH-pyrazol-5-yl]amino ⁇ -5- methoxybenzoate (83 mg, 0.21 mmol) (step 3) was dissolved in THF (3.O mL), and a solution of LiOH-H 2 O (26.5 mg, 0.63 mmol) in water (1.0 mL) was added, followed by a small amount of MeOH to homogenize the mixture. After stirring for 15 h at rt at 40 0 C, the reaction mixture was cooled, the organic solvent removed under reduced pressure and the aq layer acidified by addition of 2N HCl.
  • Step 2 Preparation of l-(3,6-dimethylpyrazin-2-yl)-3-ethyl-lH-pyrazol-5-amine
  • Step 3 Preparation of methyl 2- ⁇ ri-(3,6-dimethylpyrazin-2-yl)-3-ethyl-lH-pyrazol-5-yll amino ⁇ -5-methylbenzoate
  • the mixture was cooled to rt, filtered through a Celite plug using ethyl acetate as eluent, concentrated to dryness, and subjected to column chromatography purification using a gradient elution from 10% to 20% EtOAc in hexane to afford 1.62 g (67%) of the desired product.
  • Step 4 Preparation of methyl 2- ⁇ r4-bromo-l-(3,6-dimethylpyrazin-2-yl)-3-ethyl-lH- pyrazol-5-yll amino I -5-methylbenzoate
  • Step 5 Preparation of methyl 2-(ri-(3,6-dimethylpyrazin-2-yl)-3-ethyl-4-pyridin-3-yl-lH- pyrazol-5-yll amino ⁇ -5-methylbenzoate
  • Step 6 Preparation of 2- ⁇ ri-(3,6-dimethylpyrazin-2-yl)-3-ethyl-4-pyridin-3-yl-lH-pyrazol- 5-vHamino
  • Step 4 Preparation of methyl 5-(trifluoromethoxy)-2- ⁇ r(trifluoromethyl)sulfonvnoxy ⁇ benzoate
  • Step 5 Preparation of methyl 2- ⁇ r3-ethyl-l-(3-methylpyridin-2-yl)-lH-pyrazol-5-vHamino ⁇ - 5-(trifruoromethoxy)benzoate
  • Step 6 Preparation of methyl 2- ⁇ r4-bromo-3-ethyl-l-f3-methylpyridin-2-yl)-lH-pyrazol-5- yll amino ⁇ -5-(trifluorometlioxy)benzoate
  • Step 7 Preparation of 2- ⁇ r3-ethyl-4-(6-methoxypyridin-3-yl)-l-(3-methylpyridin-2-yl)-lH- pyrazol-5-yll amino ⁇ -5-(trifluoromethoxy)benzoic acid
  • Step 3 Preparation of 5-Bromo-2-r3-cyclopropyl-l-(3-methyl-pyridin-2-yl)-lH-pyrazol-5- ylaminol-benzoic acid methyl ester
  • Step 5 Preparation of 2-r4-Bromo-3-cyclopropyl-l-(3-methyl-pyridin-2-yl)-lH-pyrazol-5- ylaminol-5-cvclopropyl-benzoic acid methyl ester
  • Step 7 Preparation of 5-Cyclopropyl-2-r3-cvclopropyl-4-(6-methoxy-pyridin-3-yl)-l-(3- methyl-pyridin-2-yl)-lH-pyrazol-5-ylaminol-benzoic acid
  • Step 1 Synthesis of 2-r3-(3-Ethylphenyl)-l-(3-methylpyridin-2-yl)-lH-pyrazol-5-ylaminol- 5-fluorobenzoic acid methyl ester
  • Step 2 Preparation of 2-r3-(3-Ethylphenyl)-l-(3-methylpyridin-2-yl)-lH-pyrazol-5- ylaminol-5-fluorobenzoic acid
  • Step 1 Preparation of l-(3,6-Dimethylpyrazm-2-yl)-3-(3-ethylphenyl)-lH- ⁇ yrazol-5-amine
  • Step 2 Preparation of 2-ri-C3,6-Dimethylpyrazin-2-yl)-3-( ' 3-ethylphenyl)-lH-Pyrazol-5- ylaminol -benzoic acid methyl ester
  • the mixture was cooled to rt, filtered through a Celite plug using ethyl acetate as eluent, concentrated to dryness, and subjected to HPLC purification using a gradient elution from 30% to 100% acetonitrile in water to afford 72 mg (45%) of the desired product.
  • Step 3 Preparation of l-r2-(3,6-Dimethylpyrazin-2-yl)-3-(3-ethylphenyl)-lH-pyrazol-5- ylaminol -benzoic acid
  • 3,5-Dimethylpyridine N-oxide (10.0 g, 81.2 mmol) was consecutively treated with concentrated nitric acid (10.1 mL) and concentrated sulfuric acid (43.3 mL). The resulting mixture was stirred at 110 0 C for 1.5 h. After cooling to room temperature, the mixture was poured into ice water and the pH was adjusted to 12 by addition of solid potassium hydroxide. The resulting precipitate was collected by filtration. The mother liquor was extracted with ethyl acetate. The combined organic extracts were washed with brine, dried over MgSO 4 and the solvents were evaporated off. The residue was combined with the solid obtained by filtration yielding 3,5-dimethyl-4-nitropyridine N-oxide (7.5 g, 50%) which was used for the next step without further purification.
  • 3,5-Dimethyl-4 ⁇ nitropyridine (3.78 g, 21.4 mmol) was dissolved in hydrazine monohydrate (75 mL) and the resulting solution was stirred at 100 0 C for 1 h. The volatiles were removed under reduced pressure and the residue was dissolved in ethyl actetate (100 mL). The solution was washed with a mixture of brine and sodium hydroxide solution, dried over MgSO 4 and concentrated under reduced pressure yielding 4-hydrazino-3,4-dimethyl pyridine (2.2 g, 75%).
  • Step 2 Preparation of l-(3,5-dimethylpyridin-4-yl)-3-(3-ethylphenyl)-lH-pyrazol ⁇ 5-amine
  • Step 3 Preparation of methyl 2- ⁇ ri-(3,5-dimethylpyridin-4-yl)-3-(3-ethylphenyl)- lH-pyrazol-5-y ⁇ amino Ibenzoate
  • Step 4 Preparation of 2-ri-(3,5-dimethylpyridin-4-yl)-3-(3-ethvbhenyl)-lH-pyrazol-5- yliaminobenzoic acid hydrochloride
  • Step 1 Preparation of methyl 2- ⁇ [l-( ' 3,5-dimethylpyridm-4-yl)-3-(3-ethylphenyl)- lH-pyrazol-5-yl1arnino)-5-fluorobenzoate
  • Step 2 Preparation of 2-ri-(3.5-dimethylpyridin-4-yl)-3-(3-ethylphenylVlH-pyrazol-5- vnamino-5-fluorobenzoic acid hydrochloride
  • Step 1 Preparation of 3-(3-ethylphenyl)-l-(3-trifluoromemylpyridin-2-yl)-lH-pyrazol-5- amine
  • Step 2 Preparation of 5-bromo-2-r3-f3-ethylphenyl)-l-(3-trifluoromethylpyridin-2-yl)-lH- PVrazol-5-ylaminol-benzoic acid methyl ester
  • Step 3 Preparation of 5-cvclopropyl-2-r3-(3-ethylphenyl)-l-(3-trifluoromethylpyridin-2-yl)- lH-pyrazol-5-ylaminoi-benzoic acid methyl ester
  • Step 4 Preparation of 5-cyclopropyl-2-r3-(3-ethylphenyl)-l-(3-trifluoromethylpyridin-2-yl)- lH-pyrazol-5-ylaminol-benzoic acid
  • Step 1 Preparation of 2-r3-ethyl-4-(2-methoxyphenyl)-l-(3-methylpyridin-2-yl)-lH- pyrazol-5-ylaminol-5-trifluoromethoxy-benzoic acid methyl ester
  • Step 2 Preparation of 243-ethyl-4-(2-memoxyphenylM-(3-methyl ⁇ yridm-2-yl)-lH- pyrazol-5-ylaminol -5-trifluoromethoxy-benzoic acid
  • Step 1 Preparation of l-(3-ethylphenyl)-3,3-dimercaptoprop-2-en-l-one
  • the aqueous phase was acidified with IN sulfuric acid while cooled in an ice bath and it was extracted three times with tert-butylmethylether. The organic extracts were dried over NaCl and evaporated to dryness in vacuo. This material was used in the next step without further purification.
  • Step 2 Preparation of ethyl 2- ⁇ r3-(3-ethylphenyl)-3-oxopropanethiovHamino
  • the reaction mixture consists of two major components. One was ethyl 2-aminobenzoate and the other component contained a mixture of tautomers of ethyl 2-
  • Step 3 Preparation of ethyl 2- ⁇ r3-(3-ethylphenyl)-l-(2-methylquinolin-4-yl)-lH-pyrazol-5- yliamino Ibenzoate
  • Step 4 Preparation of 2- ⁇ r3-(3-ethylphenyl)-l-(2-methylquinolin-4-yl)-lH-pyrazol-5-yl1 amino I benzoic acid hydrochloride
  • Step 1 Preparation of 3,3-dimercapto-l-phenylprop-2-en-l-one
  • the aqueous phase was acidified with IN sulfuric acid in an ice bath and then extracted three times with tert-butylmethylether. The combined organic extracts were dried over NaCl and evaporated to dryness in vacuo. This material (21 g) was used in the following step without further purification.
  • Step 2 Preparation of ethyl 2-r(3 ⁇ oxo ⁇ 3-phenylpropanethioyl)aminolbenzoate
  • Step 3 Preparation of ethyl 2- ⁇ ri-(3,5-dichloropyridin-4-yl) ⁇ 3-phenyl-lH-pyrazol-5-yll amino jbenzoate
  • Step 4 Preparation of 2- ⁇ ri-(3,5-dichloropyridin-4-yl)-3-phenyl-lH-pyrazol-5-yl1amino ⁇ benzoic acid hydrochloride
  • Step 2 Preparation of tert-butyl 2-cvano-3-(3-isopropoxyphenyl)-3-oxopropanoate
  • Step 4 Preparation of l-(3,5-dimethylpyridin-4-yl)-3-(3-isopropoxyphenyl)-lH-pyrazol- 5-amine
  • Step 5 Preparation of methyl 2- ⁇ ri-(3,5-dimethylpyridin-4-yl)-3-(3-isopropoxyphenyl)- 1 H-p yrazol-5- yll amino ⁇ -5-methylbenzoate
  • Step 6 Preparation of 2-ri-(3,5-dimethylpyridin-4-yl)-3-(3-isopropoxyphenyl)-lH-pyrazol- 5-yl1amino-5-methylbenzoic acid hydrochloride
  • 3-isopropylbenzoic acid was prepared following a known literature procedure from 1-bromo 3-isoproylbenzene (Smith, J.G.; Turle, R.A.; /. Org. Chem. 1972, 37, 126-131).
  • Step 4 Preparation of 2- ⁇ r3-(3-isopropoxyphenyl)-l-(3-methyl-2-thienyl)-lH-pyrazol- 5-vnamino
  • Step 1 Preparation of di-tert-butyl l-(4-methyl-3-thienyl)hydrazine-l,2-dicarboxylate
  • Step 4 Preparation of methyl 2- ⁇ r3-(3-ethoxyphenyl)-l-(4-methyl-3-thienyl)-lH-pyrazol-5- yll amino ⁇ -4-fluorobenzoate
  • Step 5 Preparation of 2-i r3-(3-ethoxyphenyl)-l-(4-methyl-3-thienyl)-lH-pyrazol- 5-vnamino
  • Step 1 Preparation of tert-butyl 2-cvano-3-(2-ethylpyridm-4-yl) ⁇ 3-oxopropanoate
  • Step 3 Preparation of methyl 2-i r3-f2-ethylpyridin-4-yl)-l-(2-methylphenyl)-lH- pyrazol-5-vH amino ⁇ -5-methylbenzoate
  • Step 4 Preparation of 2- ⁇ r3-(2-ethylpyridin-4-yl)-l-(2-methylphenyl)-lH-pyrazol- 5-vHarnino
  • the compounds of the present invention may be employed in the treatment of diabetes, including both type 1 and type 2 diabetes (non-insulin dependent diabetes mellitus). Such treatment may also delay the onset of diabetes and diabetic complications.
  • the compounds may be used to prevent subjects with impaired glucose tolerance from proceeding to develop type 2 diabetes.
  • Other diseases and conditions that may be treated or prevented using compounds of the invention in methods of the invention include: Maturity- Onset Diabetes of the Young (MODY) (Herman, et al., Diabetes 43:40, 1994); Latent Autoimmune Diabetes Adult (LADA) (Zimmet, et al., Diabetes Med. 11:299, 1994); impaired glucose tolerance (IGT) (Expert Committee on Classification of Diabetes Mellitus, Diabetes Care 22 (Supp. 1):S5, 1999); impaired fasting glucose (IFG) (Charles, et al., Diabetes 40:796, 1991); gestational diabetes (Metzger, Diabetes, 40:197, 1991); and metabolic syndrome X.
  • MODY Maturity- Onset Diabetes of
  • the compounds of the present invention may also be effective in such disorders as obesity, and in the treatment of atherosclerotic disease, hyperlipidemia, hypercholesteremia, low HDL levels, hypertension, cardiovascular disease (including atherosclerosis, coronary heart disease, coronary artery disease, and hypertension), cerebrovascular disease and peripheral vessel disease.
  • the compounds of the present invention may also be useful for treating physiological disorders related to, for example, cell differentiation to produce lipid accumulating cells, regulation of insulin sensitivity and blood glucose levels, (which are involved in, for example, abnormal pancreatic beta-cell function, insulin secreting tumors and/or autoimmune hypoglycemia due to autoantibodies to insulin, autoantibodies to the insulin receptor, or autoantibodies that are stimulatory to beta-cells), macrophage differentiation which leads to the formation of atherosclerotic plaques, inflammatory response, carcinogenesis, hyperplasia, adipocyte gene expression, adipocyte differentiation, reduction in the pancreatic beta-cell mass, insulin secretion, tissue sensitivity to insulin, liposarcoma cell growth, polycystic ovarian disease, chronic anovulation, hyperandrogenism, progesterone production, steroidogenesis, redox potential and oxidative stress in cells, nitric oxide synthase (NOS) production, increased gamma glutamyl trans
  • Compounds of the invention may also be used in methods of the invention to treat secondary causes of diabetes (Expert Committee on Classification of Diabetes Mellitus, Diabetes Care 22 (Supp. 1):S5, 1999).
  • Such secondary causes include glucocorticoid excess, growth hormone excess, pheochromocytoma, and drug-induced diabetes.
  • Drugs that may induce diabetes include, but are not limited to, pyriminil, nicotinic acid, glucocorticoids, phenytoin, thyroid hormone, ⁇ -adrenergic agents, ⁇ -interferon and drugs used to treat HIV infection.
  • the compounds of the present invention may be used alone or in combination with additional therapies and/or compounds known to those skilled in the art in the treatment of diabetes and related disorders.
  • the methods and compounds described herein may be used, partially or completely, in combination therapy.
  • the compounds of the invention may also be administered in combination with other known therapies for the treatment of diabetes, including PPAR agonists, sulfonylurea drugs, non-sulfonylurea secretagogues, ⁇ -glucosidase inhibitors, insulin sensitizers, insulin secretagogues, hepatic glucose output lowering compounds, insulin and anti-obesity drugs.
  • Such therapies may be administered prior to, concurrently with or following administration of the compounds of the invention.
  • Insulin includes both long and short acting forms and formulations of insulin.
  • PPAR agonist may include agonists of any of the PPAR subunits or combinations thereof.
  • PPAR agonist may include agonists of PPAR- ⁇ , PPAR- ⁇ , PPAR- ⁇ or any combination of two or three of the subunits of PPAR.
  • PPAR agonists include, for example, rosiglitazone and pioglitazone.
  • Sulfonylurea drugs include, for example, glyburide, glimepiride, chlorpropamide, and glipizide, ⁇ -glucosidase inhibitors that may be useful in treating diabetes when administered with a compound of the invention include acarbose, miglitol and voglibose.
  • Insulin sensitizers that may be useful in treating diabetes include thiazolidinediones and non-thiazolidinediones.
  • Hepatic glucose output lowering compounds that may be useful in treating diabetes when administered with a compound of the invention include metformin, such as Glucophage and Glucophage XR.
  • Insulin secretagogues that may be useful in treating diabetes when administered with a compound of the invention include sulfonylurea and non-sulfonylurea drugs: GLP-I, GIP, secretin, nateglinide, meglitinide, repaglinide, glibenclamide, glimepiride, chlorpropamide, glipizide.
  • GLP-I includes derivatives of GLP-I with longer half-lives than native GLP-I, such as, for example, fatty-acid derivatized GLP-I and exendin.
  • compounds of the invention are used in combination with insulin secretagogues to increase the sensitivity of pancreatic beta-cells to the insulin secretagogue.
  • Anti-obesity drugs include ⁇ -3 agonists, CB-I antagonists, appetite suppressants, such as, for example, sibutramine (Meridia), and lipase inhibitors, such as, for example, orlistat (Xenical).
  • Compounds of the invention may also be used in methods of the invention in combination with drugs commonly used to treat lipid disorders in diabetic patients. Such drugs include, but are not limited to, HMG-CoA reductase inhibitors, nicotinic acid, bile acid sequestrants, and fibric acid derivatives.
  • Compounds of the invention may also be used in combination with anti-hypertensive drugs, such as, for example, ⁇ -blockers and ACE inhibitors.
  • Such co-therapies may be administered in any combination of two or more drugs (e.g., a compound of the invention in combination with an insulin sensitizer and an anti- obesity drug). Such co-therapies may be administered in the form of pharmaceutical compositions, as described above.
  • subject includes mammals (e.g., humans and animals).
  • treatment includes any process, action, application, therapy, or the like, wherein a subject, including a human being, is provided medical aid with the object of improving the subject's condition, directly or indirectly, or slowing the progression of a condition or disorder in the subject.
  • combination therapy means the administration of two or more therapeutic agents to treat a diabetic condition and/or disorder.
  • administration encompasses co-administration of two or more therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each inhibitor agent.
  • administration encompasses use of each type of therapeutic agent in a sequential manner.
  • terapéuticaally effective means the amount of each agent administered that will achieve the goal of improvement in a diabetic condition or disorder severity, while avoiding or minimizing adverse side effects associated with the given therapeutic treatment.
  • pharmaceutically acceptable means that the subject item is appropriate for use in a pharmaceutical product. Based on well known assays used to determine the efficacy for treatment of conditions identified above in mammals, and by comparison of these results with the results of known medicaments that are used to treat these conditions, the effective dosage of the compounds of this invention can readily be determined for treatment of each desired indication.
  • the amount of the active ingredient (e.g., compounds) to be administered in the treatment of one of these conditions can vary widely according to such considerations as the particular compound and dosage unit employed, the mode of administration, the period of treatment, the age and sex of the patient treated, and the nature and extent of the condition treated.
  • the total amount of the active ingredient to be administered may generally range from about 0.0001 mg/kg to about 200 mg/kg, and preferably from about 0.01 mg/kg to about 200 mg/kg body weight per day.
  • a unit dosage may contain from about 0.05 mg to about 1500 mg of active ingredient, and may be administered one or more times per day.
  • the daily dosage for administration by injection may be from about 0.01 to about 200 mg/kg.
  • the daily rectal dosage regimen may be from 0.01 to 200 mg/kg of total body weight.
  • the transdermal concentration may be that required to maintain a daily dose of from 0.01 to 200 mg/kg.
  • the specific initial and continuing dosage regimen for each patient will vary according to the nature and severity of the condition as determined by the attending diagnostician, the activity of the specific compound employed, the age of the patient, the diet of the patient, time of administration, route of administration, rate of excretion of the drug, drug combinations, and the like.
  • the desired mode of treatment and number of doses of a compound of the present invention may be ascertained by those skilled in the art using conventional treatment tests.
  • the compounds of this invention may be utilized to achieve the desired pharmacological effect by administration to a patient in need thereof in an appropriately formulated pharmaceutical composition.
  • a patient for the purpose of this invention, is a mammal, including a human, in need of treatment for a particular condition or disease. Therefore, the present invention includes pharmaceutical compositions which are comprised of a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the invention.
  • a pharmaceutically acceptable carrier is any carrier which is relatively non-toxic and innocuous to a patient at concentrations consistent with effective activity of the active ingredient so that any side effects ascribable to the carrier do not vitiate the beneficial effects of the active ingredient.
  • a therapeutically effective amount of a compound is that amount which produces a result or exerts an influence on the particular condition being treated.
  • the compounds described herein may be administered with a pharmaceutically-acceptable carrier using any effective conventional dosage unit forms, including, for example, immediate and timed release preparations, orally, parenterally, topically, or the like.
  • the compounds may be formulated into solid or liquid preparations such as, for example, capsules, pills, tablets, troches, lozenges, melts, powders, solutions, suspensions, or emulsions, and may be prepared according to methods known to the art for the manufacture of pharmaceutical compositions.
  • the solid unit dosage forms may be a capsule which can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers such as lactose, sucrose, calcium phosphate, and corn starch.
  • the compounds of this invention may be tableted with conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders such as acacia, cornstarch, or gelatin; disintegrating agents intended to assist the break-up and dissolution of the tablet following administration such as potato starch, alginic acid, corn starch, and guar gum; lubricants intended to improve the flow of tablet granulation and to prevent the adhesion of tablet material to the surfaces of the tablet dies and punches, for example, talc, stearic acid, or magnesium, calcium or zinc stearate; dyes; coloring agents; and flavoring agents intended to enhance the aesthetic qualities of the tablets and make them more acceptable to the patient.
  • conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders such as acacia, cornstarch, or gelatin
  • disintegrating agents intended to assist the break-up and dissolution of the tablet following administration such as potato starch, alginic acid, corn starch, and
  • Suitable excipients for use in oral liquid dosage forms include diluents such as water and alcohols, for example, ethanol, benzyl alcohol, and polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent.
  • Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance tablets, pills or capsules may be coated with shellac, sugar or both.
  • Dispersible powders and granules are suitable for the preparation of an aqueous suspension. They provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, those sweetening, flavoring and coloring agents described above, may also be present.
  • the pharmaceutical compositions of this invention may also be in the form of oil-in- water emulsions.
  • the oily phase may be a vegetable oil such as liquid paraffin or a mixture of vegetable oils.
  • Suitable emulsifying agents may be (1) naturally occurring gums such as gum acacia and gum tragacanth, (2) naturally occurring phosphatides such as soy bean and lecithin, (3) esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monooleate, and (4) condensation products of said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavoring agents.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil such as, for example, arachis oil, olive oil, sesame oil, or coconut oil; or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent such as, for example, beeswax, hard paraffin, or cetyl alcohol.
  • the suspensions may also contain one or more preservatives, for example, ethyl or ⁇ -propyl p-hydroxybenzoate; one or more coloring agents; one or more flavoring agents; and one or more sweetening agents such as sucrose or saccharin.
  • Syrups and elixirs may be formulated with sweetening agents such as, for example, glycerol, propylene glycol, sorbitol, or sucrose. Such formulations may also contain a demulcent, and preservative, flavoring and coloring agents.
  • sweetening agents such as, for example, glycerol, propylene glycol, sorbitol, or sucrose.
  • Such formulations may also contain a demulcent, and preservative, flavoring and coloring agents.
  • the compounds of this invention may also be administered parenterally, that is, subcutaneously, intravenously, intramuscularly, or interperitoneally, as injectable dosages of the compound in a physiologically acceptable diluent with a pharmaceutical carrier which may be a sterile liquid or mixture of liquids such as water, saline, aqueous dextrose and related sugar solutions; an alcohol such as ethanol, isopropanol, or hexadecyl alcohol; glycols such as propylene glycol or polyethylene glycol; glycerol ketals such as 2,2- dimethyl-l,l-dioxolane ⁇ 4-methanol, ethers such as poly(ethyleneglycol) 400; an oil; a fatty acid; a fatty acid ester or glyceride; or an acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant such as a soap or a detergent, suspending agent such as pectin,
  • Suitable fatty acids include oleic acid, stearic acid, and isostearic acid.
  • Suitable fatty acid esters are, for example, ethyl oleate and isopropyl myristate.
  • Suitable soaps include fatty alkali metal, ammonium, and triethanolamine salts and suitable detergents include cationic detergents, for example, dimethyl dialkyl ammonium halides, alkyl pyridinium halides, and alkylamine acetates; anionic detergents, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates; nonionic detergents, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylenepolypropylene copolymers; and amphoteric detergents, for example, alkyl-beta-aminopropionates, and 2- alkylimidazoline quarternary ammonium salts, as well as mixtures.
  • suitable detergents include cationic detergents, for example, dimethyl dialkyl ammonium halides, al
  • compositions of this invention may typically contain from about 0.5% to about 25% by weight of the active ingredient in solution. Preservatives and buffers may also be used advantageously. In order to minimize or eliminate irritation at the site of injection, such compositions may contain a non-ionic surfactant having a hydrophile- lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulation ranges from about 5% to about 15% by weight.
  • the surfactant can be a single component having the above HLB or can be a mixture of two or more components having the desired HLB.
  • surfactants used in parenteral formulations are the class of polyethylene sorbitan fatty acid esters, for example, sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
  • the pharmaceutical compositions may be in the form of sterile injectable aqueous suspensions.
  • Such suspensions may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents such as, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents which may be a naturally occurring phosphatide such as lecithin, a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate, a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadecaethyleneoxycetanol, a condensation product of ethylene oxide with a partial ester derived form a fatty acid and a hexitol such as polyoxyethylene sorbitol monooleate, or a condensation product of an ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride, for example polyoxyethylene sorb
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent.
  • Diluents and solvents that may be employed are, for example, water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile fixed oils are conventionally employed as solvents or suspending media.
  • any bland, fixed oil may be employed including synthetic mono or diglycerides.
  • fatty acids such as oleic acid may be used in the preparation of injectables.
  • composition of the invention may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions may be prepared by mixing the drug (e.g., compound) with a suitable non-irritation excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • a suitable non-irritation excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritation excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such material are, for example, cocoa butter and polyethylene glycol.
  • transdermal delivery devices Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts.
  • the construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art ⁇ see, e.g., U.S. Patent No. 5,023,252, incorporated herein by reference).
  • patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
  • compositions of the invention may also contain other conventional pharmaceutically acceptable compounding ingredients, generally referred to as carriers or diluents, as necessary or desired. Any of the compositions of this invention may be preserved by the addition of an antioxidant such as ascorbic acid or by other suitable preservatives. Conventional procedures for preparing such compositions in appropriate dosage forms can be utilized,
  • compositions for its intended route of administration include: acidifying agents, for example, but are not limited to, acetic acid, citric acid, fumaric acid, hydrochloric acid, nitric acid; and alkalinizing agents such as, but are not limited to, ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium hydroxide, triethanolamine, trolamine.
  • acidifying agents for example, but are not limited to, acetic acid, citric acid, fumaric acid, hydrochloric acid, nitric acid
  • alkalinizing agents such as, but are not limited to, ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium hydroxide, triethanolamine, trolamine.
  • adsorbents e.g., powdered cellulose and activated charcoal
  • aerosol propellants e.g., carbon dioxide, CCl 2 F 2 , F 2 ClC-CClF 2 and CClF 3
  • air displacement agents e.g., nitrogen and argon
  • antifungal preservatives e.g., benzoic acid, butylparaben, ethylparaben, methylparaben, propylparaben, sodium benzoate
  • antimicrobial preservatives e.g., benzalkonium chloride, benzethonium chloride, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, phenol, phenylethyl alcohol, phenylmercuric nitrate and thimerosal
  • antioxidants e.g., ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, but
  • clarifying agents e.g., bentonite
  • emulsifying agents but are not limited to, acacia, cetomacrogol, cetyl alcohol, glyceryl monostearate, lecithin, sorbitan monooleate, polyethylene 50 stearate
  • encapsulating agents e.g., gelatin and cellulose acetate phthalate
  • flavorants e.g., anise oil, cinnamon oil, cocoa, menthol, orange oil, peppermint oil and vanillin
  • humectants e.g., glycerin, propylene glycol and sorbitol
  • levigating agents e.g., mineral oil and glycerin
  • oils e.g., arachis oil, mineral oil, olive oil, peanut
  • the compounds described herein may be administered as the sole pharmaceutical agent or in combination with one or more other pharmaceutical agents where the combination causes no unacceptable adverse effects.
  • the compounds of this invention can be combined with known anti-obesity, or with known antidiabetic or other indication agents, and the like, as well as with admixtures and combinations thereof.
  • compositions which are comprised of an inert carrier and an effective amount of a compound identified by the methods described herein, or a salt or ester thereof.
  • An inert carrier is any material which does not interact with the compound to be carried and which lends support, means of conveyance, bulk, traceable material, and the like to the compound to be carried.
  • An effective amount of compound is that amount which produces a result or exerts an influence on the particular procedure being performed.
  • Formulations suitable for subcutaneous, intravenous, intramuscular, and the like; suitable pharmaceutical carriers; and techniques for formulation and administration may be prepared by any of the methods well known in the art ⁇ see, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 20 th edition, 2000). The following examples are presented to illustrate the invention described herein, but should not be construed as limiting the scope of the invention in any way.
  • a capsule formula is prepared from: Compound of this invention 10 mg
  • the components are blended, passed through an appropriate mesh sieve, and filled into hard gelatin capsules.
  • a tablet is prepared from:
  • Compound of this invention 25 mg Cellulose, microcrystalline 200 mg
  • aqueous and non-aqueous coatings may be applied to increase palatability, improve elegance and stability or delay absorption.
  • a mg/mL solution of the desired compound of this invention is made using sterile, injectable water, and the pH is adjusted if necessary.
  • the solution is diluted for administration with sterile 5% dextrose and is administered as an IV infusion.
  • Intramuscular suspension The following intramuscular suspension is prepared:
  • Compound of this invention 50 ⁇ g/mL
  • the suspension is administered intramuscularly.
  • Hard Shell Capsules A large number of unit capsules are prepared by filling standard two-piece hard galantine capsules each with powdered active ingredient, 150 mg of lactose, 50 mg of cellulose, and 6 mg of magnesium stearate.
  • a mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil, or olive oil is prepared and injected by means of a positive displacement pump into molten gelatin to form soft gelatin capsules containing the active ingredient.
  • the capsules are washed and dried.
  • the active ingredient can be dissolved in a mixture of polyethylene glycol, glycerin and sorbitol to prepare a water miscible medicine mix.
  • the active ingredient is mixed in a liquid containing ingredient such as sugar, gelatin, pectin, and sweeteners. These liquids are solidified into solid tablets or caplets by freeze drying and solid state extraction techniques.
  • the drug compounds may be compressed with viscoelastic and thermoelastic sugars and polymers or effervescent components to produce porous matrices intended for immediate release, without the need of water.
  • Demonstration of the activity of the compounds of the present invention may be accomplished through in vitro, ex vivo, and in vivo assays that are well known in the art.
  • in vitro, ex vivo, and in vivo assays that are well known in the art.
  • the following assays may be used.
  • Insulin secretion of dispersed rat islets mediated by a number of compounds of the present invention was measured as follows. Islets of Langerhans, isolated from male Sprague-Dawley rats (200-250 g), were digested using collagenase. The dispersed islet cells were treated with trypsin, seeded into 96 V-bottom plates, and pelleted. The cells were then cultured overnight in media with or without compounds of this invention. The media was aspirated, and the cells were pre-incubated with Krebs-Ringer-HEPES buffer containing 3 niM glucose for 30 minutes at 37°C.
  • the pre-incubation buffer was removed, and the cells were incubated at 37°C with Krebs-Ringer-HEPES buffer containing the appropriate glucose concentration (e.g., 8 mM) with or without compounds for an appropriate time.
  • the appropriate glucose concentration e.g. 8 mM
  • an appropriate concentration of GLP-I or forskolin was also included.
  • a portion of the supernatant was removed and its insulin content was measured by SPA. The results were expressed as "fold over control" (FOC), in accordance with standard practice in the field.
  • Compounds of Formula (T) of the current invention are also useful for identifying their associated biological target(s) (e.g., nucleic acids, peptides, polypeptides, proteins, carbohydrates, lipids, or other molecules) effecting the functional response of insulin secretion.
  • biological target(s) e.g., nucleic acids, peptides, polypeptides, proteins, carbohydrates, lipids, or other molecules
  • targets, or protein molecules that are modulated by the compounds of present invention can be identified by several means.
  • one such method of target identification can be accomplished, by photoaffinity labeling techniques well-known in the art.
  • compounds of Formula (I) that contain a photoactive group, such as a benzoylphenyl group are prepared and additionally labeled with a radioactive isotope such as tritium.
  • pancreatic beta-cell lysate homogenate or any biological sample, such as a sample obtained from an organism (e.g., mammal) or from components (e.g., cells, biological tissue or fluid) of an organism, cell line or tissue culture sample; or the sample may be a sample derived from a patient including, but are not limited to, tissue or cells therefrom) containing the suspected target(s), incubated for a period of time sufficient to effect association of the probe molecule with the target protein, then the mixture is irradiated with light at the wavelength of the photoactive group of the probe molecule.
  • any biological sample such as a sample obtained from an organism (e.g., mammal) or from components (e.g., cells, biological tissue or fluid) of an organism, cell line or tissue culture sample; or the sample may be a sample derived from a patient including, but are not limited to, tissue or cells therefrom
  • the mixture is irradiated with light at the wavelength of the photoactive group of the probe molecule.
  • the protein and probe molecule that become covalently bound as a result of the irradiation is then purified using standard methods, facilitated by the radioactivity of probe/target complex as a means to differentiate it from the rest of the lysate mixture.
  • Identification of the purified protein (the probe/target complex) is then conducted using methods well described in the art ⁇ see, e.g., Dorman, et al., Tibtech. 18:64-77, 2000).
  • Another method using the compounds of Formula (I) to identify the biological target effecting the functional response of insulin secretion is the so called drug "pull-down" experiments (see, e.g., Graves, et al., Rec. Prog. Horm. Res. 58:1-24, 2003).
  • Formula (I) compounds containing functional groups that are suitable for chemical coupling may be coupled to a commercially available polymer (resins) containing a suitably reactive linker group.
  • a commercially available polymer resins
  • the polymeric beads containing immobilized Formula (I) compound may then be used as bait for appropriate pancreatic beta-cell tissue lysates, by allowing the polymer beads to come in contact with the lysate, incubating for a period of time sufficient for the target proteins to form a complex with the polymer, removing the unbound protein material from the polymer, and cleaving of the bound protein from the polymer.
  • purified protein target(s) of interest may then be identified by mass spectrometric analysis using techniques well know in the art ⁇ see, e.g., Kim, et al., Biochem. MoI. Biol. 36:299-304, 2003.

Abstract

La présente invention concerne des composés d'anilinopyrazole représentés par la formule (I) dans laquelle R3 désigne un noyau hétéroaromatique à 5 ou 6 chaînons qui est éventuellement fusionné à phényle, ledit hétérocycle ou hétérocycle fusionné étant éventuellement substitué, X désigne acide carboxylique, ester ou amide, ou sulfonamide et les groupes restants sont tels que définis dans la description. Cette invention concerne également des compositions pharmaceutiques contenant ces matériaux ainsi que des méthodes permettant de traiter le diabète et des troubles associés à l'aide de ces matériaux.
PCT/US2006/033957 2005-08-31 2006-08-31 Derives d'anilinopyrazole utilises dans le traitement du diabete WO2007027842A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002620425A CA2620425A1 (fr) 2005-08-31 2006-08-31 Derives d'anilinopyrazole utilises dans le traitement du diabete
EP06802675A EP1928455A1 (fr) 2005-08-31 2006-08-31 Derives d'anilinopyrazole utilises dans le traitement du diabete
JP2008529258A JP2009506127A (ja) 2005-08-31 2006-08-31 糖尿病の処置に有用なアニリノピラゾール誘導体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71314605P 2005-08-31 2005-08-31
US60/713,146 2005-08-31

Publications (1)

Publication Number Publication Date
WO2007027842A1 true WO2007027842A1 (fr) 2007-03-08

Family

ID=37607359

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/033957 WO2007027842A1 (fr) 2005-08-31 2006-08-31 Derives d'anilinopyrazole utilises dans le traitement du diabete

Country Status (4)

Country Link
EP (1) EP1928455A1 (fr)
JP (1) JP2009506127A (fr)
CA (1) CA2620425A1 (fr)
WO (1) WO2007027842A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029605A1 (en) * 2006-10-02 2010-02-04 Irm Llc Compounds and compositions as protein kinase inhibitors
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
WO2010132598A1 (fr) * 2009-05-13 2010-11-18 Amgen Inc. Composés hétéroaryle en tant qu'inhibiteurs des pikk
EP2266973A1 (fr) 2009-05-29 2010-12-29 Bayer CropScience AG Pyrazinylpyrazole
WO2011012674A1 (fr) 2009-07-31 2011-02-03 N.V. Organon Dihydrobenzoindazoles
WO2011057984A1 (fr) 2009-11-11 2011-05-19 Bayer Cropscience Ag Nouveaux composés diazinyle-pyrazolyle
US8143424B2 (en) 2007-06-06 2012-03-27 Torrent Pharmaceuticals Ltd. Thyroid like compounds
DE102010063691A1 (de) 2010-12-21 2012-06-21 Bayer Animal Health Gmbh Ektoparasitizide Wirkstoffkombinationen
WO2013046041A1 (fr) * 2011-09-30 2013-04-04 Synovo Gmbh Pyridinylpyrazoles destinés à être utilisés comme modulateurs de kinase dans le traitement du cancer
WO2012031061A3 (fr) * 2010-09-01 2013-04-25 E. I. Du Pont De Nemours And Company Pyrazoles fongicides et mélanges associés
WO2014067962A1 (fr) 2012-10-31 2014-05-08 Bayer Cropscience Ag Nouveaux composés hétérocycliques utilisés comme agents de lutte contre les nuisibles
US9062005B2 (en) 2009-03-03 2015-06-23 E I Du Pont De Nemours And Company Fungicidal pyrazoles
US10015966B2 (en) 2012-02-01 2018-07-10 E I Du Pont De Nemours And Company Fungicidal pyrazole mixtures

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113984726B (zh) * 2021-10-20 2024-02-02 上海大学 一种氨基苯硼酸功能化磁珠/乙二醛修饰dna检测汞离子的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1270572A1 (fr) * 2000-03-27 2003-01-02 Takeda Chemical Industries, Ltd. Derives de pyrazole condense, procede de production et utilisation
WO2004050651A1 (fr) * 2002-11-27 2004-06-17 Bayer Pharmaceuticals Corporation Derives d'anilinopyrazole destines au traitement du diabete

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL134200C (fr) * 1960-04-14
JP2001342188A (ja) * 2000-03-27 2001-12-11 Takeda Chem Ind Ltd 縮合ピラゾール誘導体、その製造法および用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1270572A1 (fr) * 2000-03-27 2003-01-02 Takeda Chemical Industries, Ltd. Derives de pyrazole condense, procede de production et utilisation
WO2004050651A1 (fr) * 2002-11-27 2004-06-17 Bayer Pharmaceuticals Corporation Derives d'anilinopyrazole destines au traitement du diabete

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Expert Committee on Classification of Diabetes Mellitus", DIABETES CARE, vol. 22, no. 1, 1999, pages 5
"Expert Committee on Classification of Diabetes Mellitus", DIABETES CARE, vol. 22, no. 1, 1999, pages S5
CHARLES ET AL., DIABETES, vol. 40, 1991, pages 796
HERMAN ET AL., DIABETES, vol. 43, 1994, pages 40
METZGER, DIABETES, vol. 40, 1991, pages 197
ZIMMET ET AL., DIABETES MED., vol. 11, 1994, pages 299

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029605A1 (en) * 2006-10-02 2010-02-04 Irm Llc Compounds and compositions as protein kinase inhibitors
US8202876B2 (en) * 2006-10-02 2012-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
US8378118B2 (en) 2007-06-06 2013-02-19 Torrent Pharmaceuticals Ltd. Pyrazole-based thyroid receptor compounds
US8143424B2 (en) 2007-06-06 2012-03-27 Torrent Pharmaceuticals Ltd. Thyroid like compounds
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
US10448639B2 (en) 2009-03-03 2019-10-22 Fmc Corporation Fungicidal pyrazoles
US9655361B2 (en) 2009-03-03 2017-05-23 E I Du Pont De Nemours And Company Fungicidal pyrazoles
US9062005B2 (en) 2009-03-03 2015-06-23 E I Du Pont De Nemours And Company Fungicidal pyrazoles
WO2010132598A1 (fr) * 2009-05-13 2010-11-18 Amgen Inc. Composés hétéroaryle en tant qu'inhibiteurs des pikk
AU2010249040B2 (en) * 2009-05-13 2013-08-22 Amgen Inc. Heteroaryl compounds as PIKK inhibitors
EP2266973A1 (fr) 2009-05-29 2010-12-29 Bayer CropScience AG Pyrazinylpyrazole
US8513260B2 (en) 2009-05-29 2013-08-20 Bayer Cropscience Ag Pyrazinylpyrazoles
US20120190687A1 (en) * 2009-05-29 2012-07-26 Bayer Cropscience Ag Pyrazinylpyrazoles
WO2011012674A1 (fr) 2009-07-31 2011-02-03 N.V. Organon Dihydrobenzoindazoles
WO2011057984A1 (fr) 2009-11-11 2011-05-19 Bayer Cropscience Ag Nouveaux composés diazinyle-pyrazolyle
US8629273B2 (en) 2009-11-11 2014-01-14 Bayer Intellectual Property Gmbh Diazinylpyrazolyl compounds
WO2012031061A3 (fr) * 2010-09-01 2013-04-25 E. I. Du Pont De Nemours And Company Pyrazoles fongicides et mélanges associés
US9107412B2 (en) 2010-09-01 2015-08-18 E I Du Pont De Nemours And Company Fungicidal pyrazoles and their mixtures
US9596853B2 (en) 2010-09-01 2017-03-21 E I Du Pont De Nemours And Company Fungicidal pyrazoles and their mixtures
US9066945B2 (en) 2010-12-21 2015-06-30 Bayer Intellectual Property Gmbh Ectoparasiticidal active substance combinations
WO2012084852A2 (fr) 2010-12-21 2012-06-28 Bayer Animal Health Gmbh Combinaisons de principes actifs ectoparasiticides
DE102010063691A1 (de) 2010-12-21 2012-06-21 Bayer Animal Health Gmbh Ektoparasitizide Wirkstoffkombinationen
WO2013046041A1 (fr) * 2011-09-30 2013-04-04 Synovo Gmbh Pyridinylpyrazoles destinés à être utilisés comme modulateurs de kinase dans le traitement du cancer
US9416123B2 (en) 2011-09-30 2016-08-16 Synovo Gmbh Kinase modulators for the treatment of cancer
US10015966B2 (en) 2012-02-01 2018-07-10 E I Du Pont De Nemours And Company Fungicidal pyrazole mixtures
WO2014067962A1 (fr) 2012-10-31 2014-05-08 Bayer Cropscience Ag Nouveaux composés hétérocycliques utilisés comme agents de lutte contre les nuisibles

Also Published As

Publication number Publication date
JP2009506127A (ja) 2009-02-12
CA2620425A1 (fr) 2007-03-08
EP1928455A1 (fr) 2008-06-11

Similar Documents

Publication Publication Date Title
WO2007027842A1 (fr) Derives d'anilinopyrazole utilises dans le traitement du diabete
US7517878B2 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
US20080064734A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
US7371767B2 (en) Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
US8404856B2 (en) Non-nucleoside reverse transcriptase inhibitors
JP6962941B2 (ja) Ａｐｊ受容体アゴニストとしての４−ヒドロキシ−３−スルホニルピリジン−２（１ｈ）−オン
JP3256513B2 (ja) ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
US20160151337A1 (en) Annelated pyrroles and their use as crac inhibitors
CN111406054B (zh) 作为组蛋白脱乙酰基酶6抑制剂的1，2，4-噁二唑衍生物
US20080009531A1 (en) 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes
TW201103905A (en) 5-alkynyl-pyridines
CA2743489A1 (fr) Amines bicycliques substituees pour le traitement du diabete
TW202329944A (zh) Ampk活化劑
CN114853812A (zh) 含氧化膦基团的化合物、其制备方法及其在医药上的应用
US20060094714A1 (en) Compounds and their use to treat diabetes and related disorders
EP4069685A1 (fr) Inhibiteurs d'alcynyle- (hétéroaryl)-carboxamide hcn1
MXPA06008833A (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006802675

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2620425

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008529258

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE